Camcevi Etm is a drug owned by Accord Biopharma Inc. It is protected by 5 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 01, 2039. Details of Camcevi Etm's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11717555 | Pharmaceutical compositions having a selected release duration |
Jan, 2039
(12 years from now) | Active |
| US12133878 | Pharmaceutical compositions having a selected release duration |
Dec, 2037
(11 years from now) | Active |
| US9572857 | Pharmaceutical compositions with enhanced stability |
Aug, 2029
(3 years from now) | Active |
| US10646572 | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(6 months from now) | Active |
| US9744207 | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(6 months from now) | Active |
FDA has granted several exclusivities to Camcevi Etm. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Camcevi Etm, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Camcevi Etm.
Exclusivity Information
Camcevi Etm holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Camcevi Etm's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 25, 2028 |
US patents provide insights into the exclusivity only within the United States, but
Camcevi Etm is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Camcevi Etm's family patents as well as insights into
ongoing legal events
on those patents.
Camcevi Etm's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Camcevi Etm's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 01, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Camcevi Etm Generics:
There are no approved generic versions for Camcevi Etm as of now.
Alternative Brands for Camcevi Etm
There are several other brand drugs using the same active ingredient (Leuprolide Mesylate) as Camcevi Etm. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Accord |
|
About Camcevi Etm
Camcevi Etm is a drug owned by Accord Biopharma Inc. Camcevi Etm uses Leuprolide Mesylate as an active ingredient. Camcevi Etm was launched by Accord in 2025.
Approval Date:
Camcevi Etm was approved by FDA for market use on 25 August, 2025.
Active Ingredient:
Camcevi Etm uses Leuprolide Mesylate as the active ingredient. Check out other Drugs and Companies using Leuprolide Mesylate ingredient
Dosage:
Camcevi Etm is available in emulsion form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 21MG BASE | EMULSION | Prescription | SUBCUTANEOUS |